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OPEN
SHORT COMMUNICATION
Measurement of lentiviral vector titre and copy number by
cross-species duplex quantitative PCR
I Christodoulou1, P Patsali2,3, C Stephanou2,3, M Antoniou3, M Kleanthous1,2,4 and CW Lederer1,2,4
Lentiviruses are the vectors of choice for many preclinical studies and clinical applications of gene therapy. Accurate measurement
of biological vector titre before treatment is a prerequisite for vector dosing, and the calculation of vector integration sites per cell
after treatment is as critical to the characterisation of modiﬁed cell products as it is to long-term follow-up and the assessment of
risk and therapeutic efﬁciency in patients. These analyses are typically based on quantitative real-time PCR (qPCR), but as yet
compromise accuracy and comparability between laboratories and experimental systems, the former by using separate simplex
reactions for the detection of endogene and lentiviral sequences and the latter by designing different PCR assays for analyses in
human cells and animal disease models. In this study, we validate in human and murine cells a qPCR system for the single-tube
assessment of lentiviral vector copy numbers that is suitable for analyses in at least 33 different mammalian species, including
human and other primates, mouse, pig, cat and domestic ruminants. The established assay combines the accuracy of single-tube
quantitation by duplex qPCR with the convenience of one-off assay optimisation for cross-species analyses and with the direct
comparability of lentiviral transduction efﬁciencies in different species.
Gene Therapy (2016) 23, 113–118; doi:10.1038/gt.2015.60; published online 23 July 2015
INTRODUCTION
Lentiviral vectors (LVs) allow curative gene therapy (GT) through
genome integration, accept large payloads at high vector titre,
readily transduce non-dividing cells, have a favourable safety
proﬁle compared with other integrating viral vectors and,
depending on pseudotype, have wide tissue and host tropism,
and thus wide-ranging applicability in the ﬁeld of GT.1 Efﬁcacy and
safety of their application are critically determined by the average
vector copy number (VCN) in the corrected cell product, with
more integration sites generally giving higher transgene expres-
sion levels in gene augmentation approaches, while also
increasing the number of viral integration sites and thus the risk
of insertional mutagenesis.2 The desired VCN, as dictated by the
required expression levels and percentage of corrected cells on
the one hand and by the efﬁcacy, long-term stability and
homogeneity of transgene-derived gene expression on the other,
is approximated by application of a speciﬁc number of biologically
active vector particles to a known number of target cells. The
actual VCN in the cell product in combination with culture and
transplantation regimens, and with a possible growth advantage
of corrected cells in turn determine the average VCN in the target
tissues of treated patients post GT.
Initial biological vector titre, actual VCN in the cell product and
post-GT VCN in the patient are usually determined by the same
quantitative real-time PCR (qPCR) procedure, optimised for the
respective system under study.3 The principle of VCN determina-
tion for integrating vectors is the quantiﬁcation of proviral vector
genomes in extracted genomic DNA (gDNA) and their normal-
isation by the number of haploid host genomes against a standard
curve of plasmid dilutions or of transgenic material of known copy
number. The choice of LV and in particular of endogene target
sequences differs considerably between laboratories, but the
underlying qPCR assays almost invariably rely on (for example,
TaqMan, Applied Biosystems, Waltham, MA, USA) probe technol-
ogy instead of double-stranded DNA-integrating dyes, in order to
minimise the detection of spurious byproducts that is common to
the latter detection method. The application of labelled probes in
turn opens up the possibility of duplexing LV- and endogene-
speciﬁc qPCR assays labelled with different detection dyes, in
order to allow same-tube detection of both sequences and with
the inherent beneﬁts of removing same-sample tube-to-tube
variation and reducing reagent cost and processing time.
However, to date only the Kohn group has developed a duplex
protocol for LV VCN determination,4 which has as yet not been
used independently.5–8 Strikingly and although any GT clinical trial
is as a rule preceded by preclinical validation in non-human
disease models, only one assay, incompatible with duplex
application, has as yet been published that uses the same
endogene qPCR assay for human and animal LV-GT samples.4
Application of independent qPCR assays, however, precludes a
direct comparison of VCN quantitation between species and, on
the practical side, duplicates the effort and cost of assay
optimisation. As an overriding dilemma, the absence of a
community-wide standard quantitation assay and the habitual
underdocumentation of technical details pertaining to VCN
determination in outcome-focussed publications compromise
the comparability of VCN and vector activity per copy between
different research groups. This study therefore set out to establish
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a duplex, cross-species assay for LV VCN quantitation towards the
establishment of a community standard for VCN reporting.
RESULTS AND DISCUSSION
Aiming to establish a qPCR assay with cross-species compatibility
for human and murine sequences, we chose a published LV qPCR
assay,9 qLV (see Table 1), and selected the highly conserved poly
(rC)-binding protein 2 (PCBP2) gene from the literature,10 and a
PCBP2 region of high sequence identity and sufﬁcient length for
optimised endogene primer and probe design. The corresponding
qPCR assay, qPCBP2, has perfect sequence identity of primers and
probes for 35 different mammalian species (see Figure 1a),
including human, apes, new- and old-world monkeys, Chinese and
golden hamster, mouse, pig, domestic and wild ruminants,
delphinidae, three bat species, hedgehog, shrew and armadillo,
and sequence identity of the entire amplicon for 33 of these. In
the following, we validate the VCN assay in human and murine
cells and demonstrate the functionality of the qPCBP2 assay in
three additional species, but all of the above species are either
naturally or experimentally infected with lentiviruses (see, for
example,11) and thus possible assay targets.
Duplex PCR is subject to competition of all same-tube
amplicons, which for quantitative assays entails the conﬁrmation
of linear ampliﬁcation for all products of interest within the
prospective range and ratios of target concentrations. Following a
simple workﬂow (see Supplementary Materials and Methods 1),
we used gDNA from human and murine erythroleukaemia cell
lines (HEL and MEL, respectively) to work towards a standard assay
for 100 ng gDNA of lentivirally transduced sample. To this end, we
tested the ampliﬁcation of simplex versus duplex reactions for
combinations of 50–200 ng gDNA, in order to allow for limiting
sample amounts or considerable imprecision in spectrophotome-
trically determined DNA quantities, with lentiviral plasmid DNA
(see Supplementary Materials and Methods 2). We used LV
plasmid amounts equivalent to VCN 0.16 up to 20 in 100 ng of
gDNA, adjusting plasmid amounts for the respective genome size
and arguing that a VCN outside this range would not be used for
titre calculations, and that for therapeutic applications a lower
VCN would be insufﬁcient and a higher VCN would carry an
unacceptably high risk of insertional mutagenesis.
Initial attempts to establish a duplex protocol based on the kit
routinely used in our laboratory for simplex detections (TaqMan
2× PCR Master Mix, Applied Biosystems) led to a depression of
amplicon detection in duplex compared with equivalent simplex
reactions when the alternative template became more abundant
within physiological and routine experimental parameters (VCN
⩾ 1.6 or gDNA ⩾ 100 ng; data not shown). This nonlinear
behaviour of duplex reactions persisted despite modiﬁcation of
a multitude of parameters relevant to qPCR efﬁciency and
amplicon competition (see Materials and Methods), but
disappeared after a switch to the 2 × Multiplex PCR Master Mix
(Qiagen, Hilden, Germany).
The dedicated multiplex kit in combination with qLV and
qPCBP2 allowed us to established a standardised duplex protocol
(see Supplementary Materials and Methods 3 and 4) with extreme
correspondence between expected and observed values for LV
detection (Supplementary Figure S1) and gDNA detection
(Supplementary Figure S2), and between simplex and duplex
detection of LV (Figure 2a and Supplementary Figure S3) and
gDNA (Figure 2b) within the above parameters. The qPCR duplex
assay displayed average ampliﬁcation efﬁciencies of (96.8 ± 3.2)%
for qLV and of (93.3 ± 4.8)% for qPCBP2 across all combinations of
VCNs and gDNA template types and concentrations tested, as
shown in Supplementary Table S1, which also gives detailed
results for efﬁciencies and quality of ﬁt for individual
combinations.
Finally, and using gDNA from clones of MEL and HEL cells
transduced with LVs typical for GT applications, we ascertained
the consistency of the measured number of integrated proviral
copies with those obtained through an independent simplex
assay (see Figures 1b–e and Supplementary Figure S4). Subse-
quent tests of the assay with gDNA from additional species (see
Supplementary Figure S5, demonstrating use with bovine, caprine
and ovine gDNA) conﬁrm its potential applicability to a wide
range of model systems. The duplex VCN assay has since been
adopted in our laboratory for the determination of LV titres after
vector production and of VCN after transduction of human
peripheral blood-derived CD34+ cells and murine bone marrow-
derived lineage-negative cells, and has proven robust and
economical. Besides these beneﬁts in its local application, the
wide species compatibility of this assay allows its wider adoption
and thus its establishment as a standard for comparing derived
experimental and vector parameters, such as transduction
efﬁciency and activity per vector copy, between independent
lentiviral GT studies.
MATERIALS AND METHODS
Cell material for DNA extraction was wild-type and LV-transduced
HEL (92.1.7 (ATCC TIB-180)) and MEL (48 (ATCC, Manassas, VA,
USA, CRL-1913)) cell populations and clones, maintained at 37 °C,
5% CO2 and 100% relative humidity in RPMI medium, supple-
mented with 1% penicillin/streptomycin, 10% fetal bovine serum
and 1% L-glutamate (all from Life Technologies, Carlsbad, CA,
USA). The LVs used for transduction were MA821T87Q, a derivative
of the GLOBE vector12 encoding a T87Q mutation in the β-globin
open-reading frame, and pCCL.sin.cPPT.hPGK.GFP.WPRE13 for MEL
and human erythroleukaemia cells, respectively. Cell clones were
isolated by twofold limiting dilution and visual inspection of
single-cell status, followed by simplex qPCR quantiﬁcation using
LV plasmid and gDNA standard curves. The clones used here
Table 1. Primer and probe sequences for the duplex cross-species VCN qPCR assay
qPCR assay Target Function Sequence (5′ to 3′)
qLV HIV gag FW TCTCGACGCAGGACTCG
RV TACTGACGCTCTCGCACC
Probe Yakima-Yellow-ATCTCTCTCCTTCTAGCCTC-ZNA4-BHQ1
qPCBP2 PCBP2 IVS 13 FW TTGTGTCTCCAGTCTGCTTG
RV AGGTGGTGGTGGTGGTA
Probe FAM-CCCTCTCCTGGCTCTAAATGTTGTGT-BHQ1
Abbreviations: BHQ1, black hole quencher-1; FAM, 6-carboxyﬂuorescein; FW, forward primer; IVS, intervening sequence; probe, 5′ ﬂuorescently labelled and 3′
quencher-linked probe; RV, reverse primer; ZNA, zip nucleic acid cationic spermine residues. Assay qLV is based on sequences published by Amendola et al.,9
with modiﬁcations shown in italics, and recognises the gag sequence of the MA821T87Q transfer vector plasmid and of proviral integration sites. Assay qPCBP2
recognises an intronic PCBP2 region of perfect cross-species identity between mouse, human and 31 additional species for the entire amplicon.
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showed a consistent quantity ratio for the LV transgene in three
independent experiments. gDNA was extracted using either a
standard phenol:chloroform:isopropanol–chloroform extraction
method (for bovine, caprine and ovine tissues) and the FlexiGene
DNA kit (Qiagen, for cell lines). The LV plasmid standard used was
the corresponding 9771-bp plasmid encoding the MA821T87Q
transfer vector segment, with 3.26 and 3.74 pg plasmid DNA
representing a VCN of 1 in 100 ng of human (3.1 Gb per haploid
genome, GRCh37) and murine (2.7 Gb per haploid genome,
GRCm38) gDNA, respectively. Experimental procedures followed
for vector production in HEK 293T cells, vector titration and
lentiviral transduction of cells have been described elsewhere.12,14
For LV standard curves, ﬁvefold serial dilutions of 6.3 and 7.2 pg
plasmid per 25-μl reaction were used in combination with human
and murine gDNA, respectively. The curves thus represented VCN
equivalents of 20, 4, 0.8 and 0.16 for 100 ng gDNA, with circular
Figure 1. Sequence alignment of qPCBP2 and validation of qLV and qPCBP2 qPCR assays. (a) Cross-species alignment for target sequences of
the PCBP2-speciﬁc qPCR assay PCBP2 gene sequences were accessed using the UCSC Genome Browser (http://genome.ucsc.edu; Build
GRCh37/hg19) and its Vertebrate Multiz Alignment track. Perfect sequence matches for PCBP2 probe and primer sequences are highlighted.
(b–d) Duplex standard curves for qLV and qPCBP2, and same-plate ampliﬁcation of MEL clones with a known VCN of 1, 2, 3 and 4, respectively,
for the MA821T87Q LV are shown and analysed. For scatter plots, corresponding trend line formulas and curve ﬁt values (r2) are shown. All
outlier-removed reactions of the duplex assay are shown. (b) Fluorescence plot of duplex qPCR for LV plasmid standard curve in the presence
of 100 ng MEL gDNA, used for the absolute quantiﬁcation of LV integration sites in MEL clones. The cause of plateau-phase noise is unknown.
(c) Fluorescence plot of duplex qPCR for MEL clones with known numbers of viral integration sites. (d) Scatter plot of the standard curve
shown in b. The plot shows the logarithm of expected VCNs against the automatically determined threshold cycle (CT) values and provides
average CT values for each data point for qLV and qPCBP2 detection as a table insert. (e) Scatter plot for VCN determination of MEL clones
analysed in c. The plot shows the expected VCN against that determined (observed) using the standard curve in d. The expected and
observed VCN values and average CT values are additionally shown as a table insert.
Figure 2. Simplex versus duplex quantiﬁcation of LV plasmid and gDNA. The scatter plots show the correlation of template amounts
determined by simplex assay with those determined by duplex assay in the presence of varying amounts of the respective alternative
template, giving the formula of the trend line and the correlation (r2) between simplex and duplex values for each plot. (a) Quantiﬁcation of LV
plasmid DNA (VCN equivalence) in the presence of varying amounts (200, 100 and 50 ng) of murine gDNA. (b) Quantiﬁcation of murine gDNA
(ng) in the presence of varying LV plasmid DNA amounts (equivalent to VCN 0.16, 0.8 and 4).
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and linearised plasmid (using ScaI-HF (New England Biolabs, Inc.,
Ipswich, MA, USA) for linearisation) performing equivalently. PCBP2
was detected as an endogene in deﬁned amounts of gDNA, both
for transgenic samples and for standard curves, which comprised
serial dilutions to 200, 100 and 50 ng of wild-type DNA per 25-μl
reaction, either neat or laced with the MA821T87Q transfer vector
plasmid at the VCN equivalents given above. Quantiﬁcation of
viral DNA and gDNA in simplex reactions was initially performed
with the TaqMan 2× PCR Master Mix (Applied Biosystems). Of the
quantitative PCR assays (all from Metabion International AG,
Planegg/Steinkirchen, Germany), qLV for detection of LV
sequences was based on a previous publication by Amendola
et al.9 (see Table 1), and the endogene assay qPCBP2 recognised
one of the PCBP2 regions of perfect cross-species sequence
identity long enough to allow primer and probe design, and
identical amplicon composition (Vector NTI Advance 11.5,
Life Technologies) (see Figure 1a). Additional assays qLV-b
(FW 5′-TGAAAGCGAAAGGGAAACCA-3′, RV 5′-TTGCCGTGCG
CGCTTCAG-3′; Probe HEX-5′-AGCTCTCTCGACGCAGGACTCGGC-3′-
TAMRA, based on Miccio et al.12) and qPCBP2-b (FW 5′-CTGCAT
AATCGGGCGTCAAG-3′, RV 5′-GCAGCAGATCCAGTGATGGTAACCT
-3′; FAM-5′-CGCCAAAATCAATGAGATCCGTCAGATGTCT-3′-TAMRA,
which inadvertently co-ampliﬁes a human pseudogene, PCBP2P2,
with a single mismatch (underlined) in the probe sequence) were
additionally used in simplex reactions and during the optimisation
of duplex assays. Attempts to establish a reliable duplex assay for
the above range of gDNA and LV amounts included the
independent modulation of many PCR parameters, including
probe concentration (50, 100, 250 or 375 nM), primer concentra-
tion (300, 600 or 900 nM), MgCl2 concentration (3–6mM), dNTP
concentration (200–400 μM), annealing temperature (60, 62 and
64 °C) and the use of alternative qPCR assays qLV-b with qPCBP2-b
and qLV with qPCBP2.
All results shown in this study are based on the 2 × Multiplex
PCR Master Mix (Qiagen), using qPCR assays qLV and qPCBP2 in
triplicate 25-μl reactions (1 × Master Mix, 250 nM for each probe
and 300 nM for each primer), and the 7900HT Fast Real-Time PCR
System running SDS v2.4 and the standard PCR programme of
2 min 50 °C, 10min 95 °C, 40 × (15 s 95 °C, 1 min 60 °C) (all from
Applied Biosystems). To aid reproduction of the analyses
performed here, a simple workﬂow chart (Supplementary
Materials and Methods 1) and Excel (Ofﬁce 2010, Microsoft,
Redmond, WA, USA) spread sheets for the calculation of LV
plasmid and gDNA standard curves (Supplementary Materials and
Methods 2), for the preparation of reactions for 96-well plates
(Supplementary Materials and Methods 3) and for the postrun
determination of VCN (Supplementary Materials and Methods 4),
respectively, are provided as Supplementary Information. In brief,
to avoid bias in the quantiﬁcation of samples, all threshold cycle
(CT) values were determined using automatic calculation of
threshold levels in SDS v2.4. All samples were run in triplicate
reactions and outliers removed automatically before statistical
analyses (all Microsoft Excel), choosing a deviation of 2 s.d. from
the triplicate median as a cutoff value. Statistical comparisons (all
Microsoft Excel) between expected and observed VCN or gDNA
values by duplex assay, and between simplex and duplex results
for observed VCN or gDNA values were based on outlier-removed
averages of triplicate repeats. For VCN standard curves and
quantiﬁcation of LV insertion sites in cellular clones, relative and
absolute VCN values, respectively, were calculated using the ΔΔCT
method values with PCBP2 as the calibrator gene. For analyses of
expected versus observed PCBP2 values, no additional calibrator
gene was used and relative PCBP2 quantities were instead
determined by subtracting the smallest PCBP2 CT value n from
all the automatically determined CT values xi of the same run to
determine the relative quantity 2(xi− n) for each sample. (This can
be emulated in Supplementary Materials and Methods 4 by ﬁlling
in PCBP2 values for the test gene (column C)] and setting all CT
values for the calibrator (column H) to 0).
Ampliﬁcation efﬁciencies and the squared Pearson’s correlation
coefﬁcient r2 of the curve ﬁt for the log-linear phase of the
qPCR ampliﬁcation were calculated using the program LinRegPCR
(v2015.2),15 by exporting ΔRN values from the SDS v2.4 acquisition
software, dismissing outlier-removed reactions and using at least
four data points per reaction for ﬁt calculations.
VCNs of LV clones in cell lines were isolated by twofold limiting
dilution and selection of clones by visual conﬁrmation of single-
cell status after seeding. Absolute copy numbers were determined
using standard curves of gDNA dilutions and LV-plasmid dilutions
in simplex reactions based on qLV and qPCPB2, and, for MEL cells,
additional LV and PCBP2 qPCR assays. Clones moreover consis-
tently showed the expected LV quantity ratios in relative qPCR
comparisons in three independent experiments.
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